Skip to content

Patient (pt) preference for the pertuzumab–trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study

PHranceSCa is a phase II study evaluating patient preference for the fixed-dose combination of PERJETA and Herceptin for subcutaneous injection versus PERJETA and Herceptin intravenous infusions in patients with HER2-positive early breast cancer. The current mini-oral will present patient preference and satisfaction data, along with healthcare professional perception and safety data (including when switching formulations), from the primary analysis.

{{assetTitle}}

Authors {{assetAuthors}}

Published date{{formattedPublishDate}}

{{assetDescription}}

Send Via Email

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

Leave Site

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.

Leave Site Stay on Medically